STOCKHOLM, Nov. 8, 2024 /PRNewswire/ —
THIRD QUARTER (JULY – SEPTEMBER 2024)
NINE MONTHS (JANUARY – SEPTEMBER 2024)
SIGNIFICANT EVENTS DURING THE SECOND QUARTER
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
WEBCAST
CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch’s interim report for July-September 2024 in a webcast to be held in English on Friday, November 8, 2024, at 10:00 a.m. CET.
Link to webcast: RaySearch Q3, 2024
The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on November 8, 2024, at 7:45 a.m. CET.
FOR MORE INFORMATION, PLEASE CONTACT:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com
Annika Blondeau Henriksson, Interim CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
annika.henriksson@raysearchlabs.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/raysearch-laboratories/r/interim-report-july—september-2024,c4063330
The following files are available for download:
RaySearch Interim report Q3 2024 |
SOURCE RaySearch Laboratories
Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK /…
SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…
BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…
HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…
Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…
Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…